Trusted by the Life Sciences Industry
Transcript of Trusted by the Life Sciences Industry
Safe Harbor – Forward Looking Statements
This presentation contains certain forward-looking statements that involve risks and
uncertainties. Such forward-looking statements include statements regarding attempts to
identify new strategic opportunities which may include a strategic transaction, plans
regarding partnering activities, product pricing, financial forecasts. Such statements are
only predictions and the Company's actual results may differ materially from those
anticipated in these forward-looking statements. Factors that may cause such differences
include the risk that the Company may not be able to identify acceptable strategic
opportunities or conclude any strategic transaction which it does identify, the risk that
products that appeared promising in early use do not demonstrate the same utility in
larger-scale uses, the risks associated with the Company's reliance on outside financing to
meet its capital requirements, and the risks associated with the Company's reliance on
collaborative partners for shipping. Forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted, or quantified. Future events
and actual results could differ materially from those set forth in, contemplated by, or
underlying the forward-looking statements. The risks and uncertainties to which forward-
looking statements are subject include, but are not limited to, the effect of government
regulation, competition and other material risks. These factors and others are more fully
discussed in the Company's periodic reports and other filings with the Securities and
Exchange Commission.
NASDAQ: CYRX April 2017 2
Company Overview
Leading cryogenic logistics solutions for the life sciences industry
Advanced technologies, validated by life sciences clients, such as
Sanofi and Novartis
Selected to support 129 clinical trials in regenerative medicine;
including 23 of 28 top CAR-T programs
Industry’s only proprietary cryogenic shippers
with real-time condition monitoring
The cryogenic solution for FedEx, UPS and DHL
April 2017 3NASDAQ: CYRX
Strong and Growing Client Base
Biopharma
Reproductive
Medicine
Animal Health
NASDAQ: CYRX April 2017 4
NASDAQ: CYRX April 2017 5
Growth Trajectoryclin
ical tr
ials
Commercial StagePhase
I
Phase
II
Phase
III
Commercial
Stage
5853
18
2 Clients filed
BLA’s with FDA
in 2017
($15-75K) ($50-125K) ($100-250K) ($2M-20M)
* Revenue potential from clinical
to commercial
Primary Target Market: Regenerative Therapy
(a) Alliance for Regenerative Medicine.
(b) Market and Markets, 2016.
6April 2017NASDAQ: CYRX
Inflection point: Commercialization
expected to begin in 2017
Launch strategies require scalable
cryogenic logistics support
Cryoport is the only effective solution
on the market for regenerative therapy
logistics
6 BLAs for regenerative therapies
expected in 2017
Rapid growth is just beginning:
$49B regenerative market by 2021(b)
(a)
(192 in 2015)
(376 in 2015)
(63 in 2015)
The Science Behind Our Logistics Solutions
PACKAGING
CONDITION MONITORING
INFORMATION
TECHNOLOGY
LOGISTICS EXPERTISE
NASDAQ: CYRX April 2017 7
Knowhow behind our Cryoport Express ShippersTM
Engineered and validated for safe transport of
fragile biologics in dynamic shipping
conditions
SmartPak II™ Condition Monitoring System
monitors and records internal and external
temperatures, humidity, openings, orientation
and other vital information in real-time
Non-hazardous liquid nitrogen dry vapor
technology eliminates cellular degradation
Cryogenically stable temperature providing
10-day dynamic holding time and enabling
global reach
International Air Transport Association (IATA)
and International Safe Transit Association
(ISTA) certified
NASDAQ: CYRX April 2017 8
Validated. Safe. Effective. Efficient.
Real-time Monitoring
NASDAQ: CYRX April 2017 9
Interactive multi-layer graphics provide
shipment chain of condition
Tiles provide current condition of shipment
Interactive map displays
shipment routing
Reporting
Secure; FDA Compliant
Chain-of-Custody and Chain-of-Condition
Risk Management
Real-time monitoring
Proactive alerts and escalation
Appropriate lane optimization
Intervention Capable
Corrections; Redirections; Interceptions; Recharging alerts
Cloud-based and flexible
CryoportalTM can integrate with manufacturers, hub services, partner systems,
etc.
Amazon cloud-based archival and solution
NASDAQ: CYRX April 2017 10
Logistics Management Platform: CryoportalTM
NASDAQ: CYRX April 2017 11
Irvine, CA
Live view 24/7/365
Proactive support
Global intervention capability
Strategic operating centers
Covering 100+ countries
Global network of partners
FedEx® Deep Frozen
Shipping Solution
powered by Cryoport®
Partner of choice for:
Global Cryogenic Solution
Summary
14
New and developing large market for
cryogenic logistics
Cellular therapies must have cryogenic logistics to deliver efficacy
Emerging regenerative medicines increasing demand for Cryoport
Regulatory requirements are expected to further increase demand
Impressive revenue growth driven by robust pipeline
4-year historical revenue CAGR of 72%
129 clinical trials drive revenue as trials progress; 18 in Phase III
First commercial biopharma client signed in 2016; two more in 2017
Advanced solutions create high barriers
to entry
Proven and validated by blue chip clients
Validated by and integrated with FedEx, UPS & DHL
Covering 100+ countries from operations centers in
California, The Netherlands and Singapore
Diversified and growing client
base
Novartis, Kite Pharma, Bristol-Myers Squibb,
bluebirdbio, Zoetis, Sanofi, Bellicum, Juno among
marquee clients
NASDAQ: CYRX April 2017
Management
Jerrell Shelton, CEO
Robert Stefanovich, CFO
Mark W. Sawicki, Ph.D., Chief Commercial Officer
Bret Bollinger, Vice President - Operations
Robert Copeland Jr., Vice President - Global Logistics
Thomas Heinzen, Vice President - Corporate Development
Board of directors
Jerrell Shelton, Chairman of the Board
Richard Berman, Lead Director
Robert Hariri, PhD, MD
Ramkumar Mandalam, Ph.D.
Edward Zecchini
15NASDAQ: CYRX April 2017
Management & Board of Directors